New Herceptin-Perjeta Formulation Shows Promising Safety and Pharmacokinetic Profile, Phase 3 Trial Shows

New Herceptin-Perjeta Formulation Shows Promising Safety and Pharmacokinetic Profile, Phase 3 Trial Shows
0
(0)

When given together with Herceptin (trastuzumab) at a fixed dose through an under-the-skin (subcutaneous) injection, Perjeta (pertuzumab) reaches levels in the blood in women with HER2-positive breast cancer that is similar to those seen when the medication is administered intravenously, data from a Phase 3 trial shows.

This new mode of administration also is faster than the standard intravenous route, the trial found.

These are the first findings of the global, randomized, open-label, FeDeriCa Phase 3 trial (NCT03493854). The study is being conducted by Genentech, a subsidiary of Roche, at 122 sites worldwide.

FeDeriCa was the first study to investigate the pharmacokinetic properties and safety profile of a subcutaneous fixed-dose combination of Perjeta-Herceptin when administered together with intravenous chemotherapy, in a group of women with HER2-positive breast cancer. Pharmacokinetics is the study of how a drug is absorbed, distributed, metabolized, and eliminated from the body — basically, what the body does to a drug.

The simultaneous administration of both medications through an under-the-skin injection was performed using Halozyme TherapeuticsENHANZE proprietary drug delivery technology. It eliminates the limitations traditionally associated with the amount of biologics that can be subcutaneously administered.

New data from FeDeriCa showed the trial met its primary outcome of non-inferiority. The subcutaneous Perjeta reached levels in the blood of study participants similar to those seen when the medication is administered intravenously.

Moreover, this new mode of administration surpassed the dosing speed of the standard intravenous route by far, the results found.

Study findings revealed the initial loading dose of subcutaneous Perjeta-Herceptin takes approximately eight minutes, with an additional five minutes for each subsequent maintenance dose. Conversely, when administered intravenously, the initial loading dose of Perjeta takes approximately 150 minutes, and between 60-150 minutes for each subsequent maintenance dose.

In addition, analyses demonstrated that the safety profile of the new fixed-dose combination of Perjeta-Herceptin was consistent with the safety profile of both medications when administered separately by an intravenous route.

“The results of the Phase 3 FeDeriCa study represent an important development for our ENHANZE drug delivery technology,” Helen Torley, president and CEO of Halozyme Therapeutics, said in a press release. “This is the first study to combine two therapeutic antibodies as a single fixed-dose subcutaneous formulation utilizing our ENHANZE technology, thereby providing patients with HER2-positive breast cancer the possibility of a faster treatment option.”

Full data from the trial will be presented at an upcoming meeting, and submitted to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 326
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • LUM Imaging System, fast track
  • Trodelvy trial results
  • Verzenio interim results
  • Tukysa approval in Australia

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?